The market size of the Global Digital Biomanufacturing Market in the year 2021 is valued at 17.53 billion and is predicted to reach 58.31 billion by the year 2030 at an 14.5% CAGR during the forecast period.
The biopharmaceutical industry's tremendous expansion has brought about new opportunities for patient care and difficulties in production. Numerous cutting-edge medical techniques make use of speciality medications that are designed to treat limited patient populations, and this indicates that substantially less drug production occurs. Manufacturers must therefore increase their operational effectiveness to lower total drug development and production costs in order to satisfy the public's need for affordable access to new medications. The Industry 4.0 paradigm will assist in achieving this objective. Using digital technologies in manufacturing processes, such as computer-aided design and computer-assisted machining, is known as "digital biomanufacturing." By enhancing manufacturing cycles, the use of these technologies can assist raise quality and safety requirements while also lowering costs. With robotic automation systems like microfluidic devices, digital biomanufacturing enables increased precision in cell cultures or tissue engineering. It also makes it possible to remotely monitor individual units using embedded sensors that transmit data back to operators via wireless networks, enabling more effective management of inventory levels during manufacturing.
The digital biomanufacturing market is segmented on the basis of application, end-user, and technology. Based on application, the market is segmented as Biomanufacturing Process Automation and Control, Bioprocess Optimization and Process Analytics, and Flexible Manufacturing. By end-user, the market is segmented into Biopharmaceutical Companies and Academic and Research Institutes. Technology segments the market into AI and IoMT Solutions, Process Analytical Technologies, Data Analytics Software, Predictive Analytics and Digital Twin Technologies, and Others.
Based on product, the bioprocess optimization and process analytics segment are accounted as a major contributor in the digital biomanufacturing market.
Digital biomanufacturing is utilized in process analytics and bioprocess optimization to track, enhance, and manage bioprocesses. By processing algorithms on a computer to be tuned for the process before being moved to an industrial system where it can run automatically without human involvement, it helps. As a result of these systems' greater accuracy and ability to decrease errors made during manual operation processes, activities become more efficient. These features are driving the bioprocess optimization and process analytics segment in the market.
AI and IoMT solutions segment witness growth at a rapid rate
The Internet of Medical Things (IoMT) was formed as a result of the increase in linked medical devices, improvements in the hardware and software that enable the collection and transfer of medical-grade data, and connectivity technologies and services. The IoMT integrates the physical and digital worlds to enhance diagnostic and treatment speed and accuracy as well as to track and adjust patient behaviour and health status in real-time. Streamlining clinical processes, information, and workflows also raises the operational productivity and effectiveness of healthcare organizations. An increasing geriatric population, with more people living longer but with many comorbidities, is partly responsible for the increase of AI and IoMT solutions.
The North America Digital Biomanufacturing market holds a significant revenue share in the region.
North America has the largest revenue share owing to its sophisticated healthcare system and substantial demand for biologics. North American businesses are increasingly opting to digitize their biologics. Furthermore, industrial organizations are investing a lot in digital technology and related assets to improve production efficiency and lower operating costs. Governments in the area are sponsoring research and development programmes to set up cutting-edge sensor networks, process controls, and data analytics in industrial firms to boost productivity and energy efficiency. Canadian manufacturers are investing in the conversion of physical factories into digital factories. They are largely concentrating on supply chain collaboration, automation and robotics, and intelligent floor sensors. As a result, the Canadian market is anticipated to display an extraordinary CAGR over the forecast period.
The key players in the Digital Biomanufacturing market have shifted their focus towards bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Digital Biomanufacturing market are Agilent Technologies Inc., Danaher Corporation, Donaldson Company, Inc., Emerson Electric Co., General Electric Company, Honeywell International Inc., SAP SE, Siemens Healthineers AG, Bota Biosciences, Culture Biosciences, e-matica srl, Exponential Genomics, Inc. (Xenomics), FabricNano, OVO Biomanufacturing and Symphony Innovation, LLC.